WHO ICTRP trial
Treatment of BCLC medium-term hepatocellular carcinoma (HCC) of randomized…
ChiCTR-IOR-17013743 · Chinese Clinical Trial Registry (ChiCTR) · Recruiting
Key facts
| Trial ID | ChiCTR-IOR-17013743 |
|---|---|
| Public title | Treatment of BCLC medium-term hepatocellular carcinoma (HCC) of randomized controlled study of Conventional TACE sequential microwave ablation (MWA) and conventional TACE alone |
| Scientific title | Treatment of BCLC medium-term hepatocellular carcinoma (HCC) of randomized controlled study of Conventional TACE sequential microwave ablation (MWA) and conventional TACE alone |
| Primary sponsor | Beijing You'an Hospital, Capital Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Recruiting |
| Study type | Interventional study |
| Phase | Other |
| Countries | China |
| Conditions | hcc |
| Interventions | control group:TACE; experimental group:TACE+MWA |
| Registration date | Dec 6, 2017 |
| Target size | control group:150; experimental group:150 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: